Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib in NRAS-mutated advanced melanoma
NCT05217303Phase 2Completed
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tunlametinib in melanoma, sponsored by Shanghai KeChow Pharmaceuticals. Started Nov 2020; status: completed.
02
Drugs
tunlametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05217303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217303.